Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITRO-BID vs GONITRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a nitrate that relaxes vascular smooth muscle by conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cyclic guanosine monophosphate (c GMP) levels, leading to vasodilation. Primarily dilates veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries.
Nitric oxide (NO) donor; activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation.
Prophylaxis of angina pectoris,Treatment of acute angina attacks,Off-label: acute myocardial infarction (limited use), heart failure with pulmonary edema (if not hypotensive)
Prevention of angina pectoris due to coronary artery disease,Acute relief of angina episodes,Prophylaxis for angina before exertion or stress
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours, then removed for 10-12 hours.
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.
Terminal half-life of nitroglycerin is 1-4 minutes; clinical effects are short-lived due to rapid redistribution and metabolism.
Terminal elimination half-life approximately 2-3 minutes for nitroglycerin; clinical effects cease within 30-60 minutes due to rapid redistribution and metabolism
Rapidly metabolized via hepatic glutathione-organic nitrate reductase to dinitrates and mononitrates; also metabolized in erythrocytes and vascular tissue.
Extensively metabolized by mitochondrial aldehyde dehydrogenase (ALDH2) in vascular smooth muscle; also metabolized by glutathione S-transferases and cytochrome P450 (CYP3A4).
Renal: <1% unchanged; extensive metabolism followed by renal excretion of metabolites, with minor biliary/fecal elimination (<5%).
Primarily renal: 80-90% as inactive metabolites (dinitrates, mononitrates); minor biliary/fecal (<10%)
Approximately 60% bound to plasma proteins (mainly albumin).
60% bound, primarily to plasma albumin
Vd approximately 3.3 L/kg, indicating extensive distribution into tissues beyond plasma volume.
Approximately 3.3 L/kg; extensive tissue distribution with high affinity for vascular smooth muscle
Sublingual: ~40% (high first-pass hepatic metabolism); Transdermal: ~72% (bypasses first-pass); Oral: <10% due to extensive hepatic metabolism.
Sublingual: 40-60%; Oral (immediate-release): <10% due to first-pass hepatic metabolism; Transdermal: 70-90% (drug-in-adhesive); Intravenous: 100%
No specific adjustment required; nitroglycerin is minimally renally excreted.
No specific dose adjustment required for renal impairment. However, use with caution in severe renal dysfunction (Cr Cl <30 m L/min) due to increased risk of hypotension and methemoglobinemia.
Child-Pugh A: no adjustment. Child-Pugh B: consider dose reduction (25-50% of normal dose). Child-Pugh C: avoid or use with extreme caution; reduce dose by 50% or more.
Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce dose by 50% due to decreased clearance. Child-Pugh C: Avoid use or use with extreme caution; consider alternative therapy.
Not routinely recommended; limited data. Intravenous: start at 0.25-0.5 mcg/kg/min, titrate by 0.5-1 mcg/kg/min every 3-5 min to effect; max 5 mcg/kg/min.
Sublingual: 5-10 mcg/kg/dose, maximum 0.3 mg per dose, may repeat every 5 minutes up to 3 doses. Intravenous: Start at 0.25-0.5 mcg/kg/min, titrate up to 1-5 mcg/kg/min based on response. Not recommended for children <1 year due to limited data.
Start at lower end of dosing range due to increased sensitivity and risk of hypotension. Sublingual: 0.3 mg initial. Transdermal: 0.2 mg/hour initially.
Initiate at lower doses due to increased sensitivity: Sublingual: 0.15-0.3 mg; Transdermal: 0.2 mg/day patch; Intravenous: Start at 5 mcg/min, titrate slowly. Monitor for hypotension and syncope. Avoid sustained-release formulations due to prolonged half-life.
No FDA boxed warning specifically for NITRO-BID. However, nitroglycerin is contraindicated with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to severe hypotension.
Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
May cause severe hypotension, especially with volume depletion; avoid in patients with hypertrophic cardiomyopathy; use caution in hepatic/renal impairment; tolerance develops with chronic use; may aggravate angina when discontinuing abruptly.
Hypotension (especially with volume depletion or diuretic therapy), reflex tachycardia, tolerance (intermittent dosing with nitrate-free interval recommended), abrupt discontinuation may cause angina rebound.
Hypersensitivity to nitrates; concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil); severe anemia; increased intracranial pressure; circulatory failure or shock; right ventricular infarction; constrictive pericarditis; cardiac tamponade.
Concomitant use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil), severe anemia, increased intracranial pressure, hypersensitivity to nitrates, acute myocardial infarction with low filling pressure.
Avoid alcohol as it may cause hypotension. No specific food interactions; maintain usual diet.
Avoid alcohol consumption as it may exacerbate nitroglycerin-induced hypotension and vasodilation. No specific food interactions documented; however, patients should maintain adequate hydration. High-fat meals may delay absorption, but sublingual route minimizes this effect. Grapefruit juice has no known interaction.
Pregnancy Category C. Animal studies have shown fetal harm (bradycardia, reduced birth weight). Inadequate human data for first trimester; avoid unless benefit outweighs risk. Second and third trimesters: associated with maternal hypotension and fetal bradycardia; use only if clearly needed.
FDA Pregnancy Category C. First trimester: no increased risk of major malformations in human studies; animal studies show fetal toxicity at high doses. Second/third trimesters: risk of fetal bradycardia, hypotension, and reduced uteroplacental perfusion; avoid near term due to risk of maternal hypotension and neonatal bradycardia.
Excreted in breast milk in small amounts; M/P ratio approximately 0.5. Although risk to infant appears low, caution is advised. Monitor infant for hypotension, methemoglobinemia (rare).
Not recommended during breastfeeding. No data on M/P ratio; minimal excretion into breast milk expected but safety not established. Potential for infant hypotension and bradycardia.
No formal dose adjustment studies in pregnancy. Pharmacokinetic changes (increased plasma volume, altered protein binding) may require upward titration. Start at lowest effective dose and titrate based on maternal hemodynamic response (BP, HR). Avoid maternal hypotension (systolic <100 mm Hg).
No standard dose adjustment required for pregnancy; use lowest effective dose. Increased plasma volume may reduce response; titrate to effect. Avoid in severe preeclampsia or volume depletion.
NITRO-BID (nitroglycerin ointment) is used for prophylaxis of angina pectoris. Apply to hairless skin, preferably chest or upper arm. Rotate sites to avoid irritation. Do not rub in; spread thin layer. Tolerance develops with continuous use; remove at bedtime to provide nitrate-free interval. Avoid in patients with severe hypotension, hypertrophic obstructive cardiomyopathy, or concurrent use of phosphodiesterase-5 inhibitors (e.g., sildenafil).
GONITRO (nitroglycerin sublingual powder) is indicated for acute relief of angina pectoris. Administer one packet (0.4 mg or 0.8 mg) at onset of chest pain; may repeat every 5 minutes up to 3 doses. Ensure patient is seated or lying down to avoid hypotension. Do not confuse with oral spray; powder must be placed under tongue. Onset within 1-3 minutes. Common side effect: headache. Contraindicated with phosphodiesterase-5 inhibitors (e.g., sildenafil) within 24-48 hours due to severe hypotension. Monitor for orthostatic hypotension.
Apply the prescribed amount to skin, do not rub in.,Wash hands after application.,Rotate application sites to prevent skin irritation.,Remove the ointment at bedtime to prevent tolerance.,Store at room temperature away from heat and open flame.,Seek emergency care if chest pain persists after use.
Take one packet at the first sign of chest pain. Empty the entire powder under your tongue and let it dissolve. Do not swallow or rinse with water.,If pain persists after 5 minutes, take a second packet. If still no relief after 5 more minutes, take a third and call 911.,Sit or lie down when taking this medication to prevent dizziness or fainting.,Avoid alcohol; it may worsen side effects like low blood pressure.,Do not use Viagra, Cialis, Levitra, or other erectile dysfunction drugs while on this medicine—serious drop in blood pressure can occur.,Headaches are common; do not stop taking the medication. Over-the-counter pain relievers may help.,Store packets at room temperature away from moisture and heat. Do not open until ready to use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITRO-BID vs GONITRO, answered by our medical review team.
NITRO-BID is a Nitrate Vasodilator that works by Nitroglycerin is a nitrate that relaxes vascular smooth muscle by conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cyclic guanosine monophosphate (c GMP) levels, leading to vasodilation. Primarily dilates veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries.. GONITRO is a Nitrate Vasodilator that works by Nitric oxide (NO) donor; activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITRO-BID and GONITRO depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITRO-BID is: Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours, then removed for 10-12 hours.. The standard adult dose of GONITRO is: Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITRO-BID and GONITRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITRO-BID is classified as Category C. Pregnancy Category C. Animal studies have shown fetal harm (bradycardia, reduced birth weight). Inadequate human data for first trimester; avoid unless benefit outweighs risk. Seco. GONITRO is classified as Category C. FDA Pregnancy Category C. First trimester: no increased risk of major malformations in human studies; animal studies show fetal toxicity at high doses. Second/third trimesters: ris. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.